Noninvasive Assessment of Fibrosis Regression after Direct-acting Antiviral Treatment in Hepatitis C Virus Patients

Yana Davidov*, Yeruham Kleinbaum, Yael Inbar, Oranit Cohen-Ezra, Ella Veitsman, Peretz Weiss, Mariya Likhter, Tania Berdichevski, Sima Katsherginsky, Avishag Hassid, Keren Tsaraf, Dana Silverberg, Ziv Ben Ari

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: New direct acting antiviral agent (DAA) therapies are associated with a high sustained virological response rate (SVR) in hepatitis C virus (HCV) patients. The understanding of the impact of SVR on fibrosis stage is limited.

Original languageEnglish
Pages (from-to)794-800
Number of pages7
JournalIsrael Medical Association Journal
Volume23
Issue number12
StatePublished - Dec 2021

Keywords

  • Chronic hepatitis C virus (HCV)
  • Direct acting antiviral agent (DAA)
  • Liver fibrosis regression
  • Noninvasive assessment
  • Shear-wave elastography (see editorial page XXX)

Fingerprint

Dive into the research topics of 'Noninvasive Assessment of Fibrosis Regression after Direct-acting Antiviral Treatment in Hepatitis C Virus Patients'. Together they form a unique fingerprint.

Cite this